NCT00308854 is a Phase 3 clinical trial of Photodynamic Therapy in Actinic Keratosis, sponsored by photonamic GmbH & Co. KG.

Who is sponsoring NCT00308854?

NCT00308854 is sponsored by photonamic GmbH & Co. KG.

What drugs are being tested in NCT00308854?

Interventions in NCT00308854: Photodynamic Therapy.

What condition does NCT00308854 study?

NCT00308854 studies Actinic Keratosis.

Is NCT00308854 still recruiting?

NCT00308854 is currently completed. Last updated 10 April 2008.

Last reviewed 2008-04-10 · How we verify

NCT00308854

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PD P 506 A or Its Placebo in Combination With Red Light for Photodynamic Therapy of Mild to Moderate Actinic Keratosis

Completed Phase 3 Last updated 10 April 2008

What this trial tests

Phase 3 trial testing Photodynamic Therapy in Actinic Keratosis in 107 participants. Completed in 1 December 2007.

Timeline

1 March 2006

Primary endpoint
1 August 2007

1 December 2007

Quick facts

Lead sponsor	photonamic GmbH & Co. KG
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	107
Start date	1 March 2006
Primary completion	1 August 2007
Estimated completion	1 December 2007
Sites	7 locations across Germany

Drugs / interventions tested

Photodynamic Therapy — full drug profile →

Conditions studied

Actinic Keratosis — all drugs for Actinic Keratosis →

Sponsor

photonamic GmbH & Co. KG — full company profile →

Who can join

18 and older, any sex, with Actinic Keratosis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Complete clinical clearance rate (CCR) of treated actinic keratosis lesions 12 weeks after PDT
Time frame: 12 weeks

Sponsor's own description

The aim of this study is to investigate whether PD P 506 A-PDT is effective in treating mild to moderate AK lesions located on the head.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Interventions for actinic keratoses.
Gupta AK, Paquet M, Villanueva E, Brintnell W. · · 2012 · cited 96× · PMID 23235610 · DOI 10.1002/14651858.cd004415.pub2
Evaluation of Long-term Clearance Rates of Interventions for Actinic Keratosis: A Systematic Review and Network Meta-analysis.
Steeb T, Wessely A, Petzold A, Brinker TJ, et al · · 2021 · cited 26× · PMID 34347015 · DOI 10.1001/jamadermatol.2021.2779

Verify or expand the search:

Other trials of Photodynamic Therapy

Trials testing the same drug.

NCT07254260 — Photodynamic Therapy and Post-Endodontic Pain in Undergraduate-Performed Treatments · completed
NCT06381154 — Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or · Phase 2 · recruiting
NCT06307548 — Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in P · Phase 1, PHASE2 · suspended
NCT06752343 — A Comparison of Photodynamic Therapy and Topical Clobetasol in Treatment of Oral Lichen Planus: a Split-Mouth Randomised · Phase 2 · completed
NCT05676801 — Effect of Photodynamic Therapy on Skin Microbiome. Single Center Study (PHOMIC-III) · EARLY_PHASE1 · unknown

Other recruiting trials for Actinic Keratosis

Currently open trials in the same condition.

NCT06778434 — The Effect of Topical Imipramine on Photodynamic Therapy-Mediated Immunosuppression on Forearms or Face on US Veterans · Phase 2 · recruiting
NCT05699603 — Testing the Efficacy of Topical Calcipotriene Plus 5-Fluorouracil Combination to Activate the Immune System Against Prec · Phase 2 · active not recruiting

Other photonamic GmbH & Co. KG trials

Trials by the same sponsor.

NCT03606122 — 5-ALA Patch-PDT of Actinic Keratosis on the Upper Extremities · Phase 2 · completed
NCT01110954 — Fluorescence-guided Resection in Breast Cancer · Phase 2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00308854 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by photonamic GmbH & Co. KG
Last refreshed: 10 April 2008

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00308854.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing